President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden ...

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. has announced the U.S. Food and Drug Administration (FDA) approval of the supplemental new drug application (SNDA) for its RNAi therapeutic, Amvuttra® (vutrisiran). This ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has dipped by 10.08%, which has investors questioning if this is right time ...

Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today that management will present a company overview at the Needham 24th Annual Virtual Healthcare Conference on ...

Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...